Combining the TMB levels with NetBio-based transcriptomic features improved the prediction of the overall survival in PD-L1 inhibitor-treated bladder cancer patients (Fig. 7b, c; Supplementary Fig. 22). The gene discussed is CD274; the disease is urinary bladder cancer.